Basel, 04 February 2025- Roche announced today that the US Food and Drug Administration has approved Susvimo ® 100 mg/mL for the treatment of diabetic macular edema, a leading cause of vision ...

Basel, 18 July 2024 Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today two-year data from the Phase III Pagoda and Pavilion studies evaluating Susvimo® (Port Delivery System with ranibizumab) for ...

The FDA has approved Roche’s Susvimo (ranibizumab injection) 100 mg/mL for intravitreal use via ocular implant to treat diabetic macular edema (DME). 1 In clinical trials, patients with DME who ...

Roche said that the Food and Drug Administration's decision was based on positive one-year results from the phase III of the Pagoda randomized study, which showed that Susvimo led to sustained ...

Roche's (RHHBY) Genentech unit has received FDA approval for its eye drug Susvimo 100 mg/mL injection for the treatment of diabetic macular edema. Read more here.

Roche's Susvimo Gets FDA Green Light for Treatment of Diabetic Retinopathy Provided by Dow Jones May 22, 2025, 4:20:00 PM. By Andrea Figueras .

Susvimo is the first and only continuous delivery treatment that offers an alternative to regular eye injections to treat diabetic macular edema (DME)With as few as two treatments per year ...

F. Hoffmann-La Roche Ltd. Two-year Phase III data presented at ASRS 2024 show Susvimo’s potential as an alternative to eye injections to treat diabetic macular edema (DME) and diabetic ...

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has approved Susvimo® (ranibizumab injection) 100 mg/mL for the treatment of diabetic macular edema ...